Brian C Gulack1, Matthew M Laughon2, Reese H Clark3, Meera N Sankar4, Christoph P Hornik5, P Brian Smith6. 1. Department of Surgery, Duke University School of Medicine, Durham, NC, United States. 2. Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States. 3. Pediatrix Medical Group, Inc., Sunrise, FL, United States. 4. Pediatrix Medical Group, San Jose, CA, United States. 5. Department of Pediatrics, Duke University School of Medicine, Durham, NC, United States; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, United States. 6. Department of Pediatrics, Duke University School of Medicine, Durham, NC, United States; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, United States. Electronic address: brian.smith@duke.edu.
Abstract
BACKGROUND: Patent ductus arteriosus (PDA) is common in extremely premature infants and associated with increased morbidity and mortality. Medical management of PDA uses either indomethacin or ibuprofen. Despite numerous studies, uncertainty exists as to which drug is safer or more effective; we sought to fill this knowledge gap. METHODS: We identified infants <28weeks gestational age discharged from neonatal intensive care units included in the Pediatrix Medical Group Clinical Data Warehouse between 2006 and 2012 who were treated with indomethacin or ibuprofen between postnatal days 2 and 14. Infants treated with both drugs or infants with a congenital malformation were excluded. We used multivariable logistic regression to determine the association of indomethacin versus ibuprofen on clinical outcomes. RESULTS: Of 6349 patients who met study criteria, 1177 (19%) received ibuprofen and 5172 (81%) received indomethacin. The median gestational age was 25weeks (interquartile range 24-26), and 2894 (46%) infants were <750g at birth. On unadjusted analysis, infants who received ibuprofen had significantly higher incidences of death prior to discharge, surgical ligation of the PDA prior to discharge, death or spontaneous intestinal perforation within 7days of therapy, death or surgical ligation of the PDA prior to discharge, and an elevated creatinine within 7days of treatment. However, on multivariable analysis, no significant differences in outcomes were observed (odds ratio for death/PDA ligation for ibuprofen vs. indomethacin=1.12 [95% CI 0.91-1.39]). CONCLUSIONS: We observed similar effectiveness and safety profiles for indomethacin and ibuprofen in the medical management of PDA in premature infants.
BACKGROUND: Patent ductus arteriosus (PDA) is common in extremely premature infants and associated with increased morbidity and mortality. Medical management of PDA uses either indomethacin or ibuprofen. Despite numerous studies, uncertainty exists as to which drug is safer or more effective; we sought to fill this knowledge gap. METHODS: We identified infants <28weeks gestational age discharged from neonatal intensive care units included in the Pediatrix Medical Group Clinical Data Warehouse between 2006 and 2012 who were treated with indomethacin or ibuprofen between postnatal days 2 and 14. Infants treated with both drugs or infants with a congenital malformation were excluded. We used multivariable logistic regression to determine the association of indomethacin versus ibuprofen on clinical outcomes. RESULTS: Of 6349 patients who met study criteria, 1177 (19%) received ibuprofen and 5172 (81%) received indomethacin. The median gestational age was 25weeks (interquartile range 24-26), and 2894 (46%) infants were <750g at birth. On unadjusted analysis, infants who received ibuprofen had significantly higher incidences of death prior to discharge, surgical ligation of the PDA prior to discharge, death or spontaneous intestinal perforation within 7days of therapy, death or surgical ligation of the PDA prior to discharge, and an elevated creatinine within 7days of treatment. However, on multivariable analysis, no significant differences in outcomes were observed (odds ratio for death/PDA ligation for ibuprofen vs. indomethacin=1.12 [95% CI 0.91-1.39]). CONCLUSIONS: We observed similar effectiveness and safety profiles for indomethacin and ibuprofen in the medical management of PDA in premature infants.
Authors: B Van Overmeire; K Smets; D Lecoutere; H Van de Broek; J Weyler; K Degroote; J P Langhendries Journal: N Engl J Med Date: 2000-09-07 Impact factor: 91.245
Authors: Scott O Guthrie; Phillip V Gordon; Victor Thomas; James A Thorp; Joyce Peabody; Reese H Clark Journal: J Perinatol Date: 2003-06 Impact factor: 2.521
Authors: Sydney R Rooney; Elaine L Shelton; Ida Aka; Christian M Shaffer; Ronald I Clyman; John M Dagle; Kelli Ryckman; Tamorah R Lewis; Jeff Reese; Sara L Van Driest; Prince J Kannankeril Journal: Pharmacogenomics Date: 2019-08 Impact factor: 2.533